Increasing Prevalence of Chronic Conditions Fuel the Europe Biosimilars Market
Biosimilars are not generics and are never treated as generics by producing companies and suppliers. Instead mentioned as bio-pharmaceuticals or follow-on biologics, biosimilars differ from generics within the entire producing process, right from the raw materials utilized in their producing. Typically, biosimilars are created primarily by the two key processes, controlled gene expression and recombinant DNA technology.
View full press release